Ticker

Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional and Insider Ownership 66.6% of Surrozen shares

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 61,515 shares, a decrease of 15.8% from the December 31st total of 73,076 shares. Currently, 4.6% of the shares of the stock are

TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price…